Evotec AG (EVO)
NASDAQ:EVO
Want to see EVO full AI Analyst Report?
EVO Stock Chart & Stats
$3.26
-$0.25(-5.45%)
At close: 4:00 PM EST
$3.26
-$0.25(-5.45%)
Day’s Range― - ―
52-Week Range$2.31 - $4.80
Previous CloseN/A
Volume32.72K
Average Volume (3M)186.07K
Market Cap
$1.11B
Enterprise Value$978.41M
Total Cash (Recent Filing)$476.19M
Total Debt (Recent Filing)$447.50M
Price to Earnings (P/E)16.1
Beta1.18
Next Earnings
May 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.29
Shares Outstanding355,755,550
10 Day Avg. Volume383,647
30 Day Avg. Volume186,074
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)1.14
Price to Sales (P/S)1.23
P/FCF Ratio-11.82
Enterprise Value/Market Cap0.88
Enterprise Value/Revenue1.24
Enterprise Value/Gross Profit8.62
Enterprise Value/Ebitda-28.06
Forecast
1Y Price Target
$4.67Price Target Upside43.15% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.27
Revenue Forecast (FY)$887.84M
Bulls Say, Bears Say
Bulls Say
AI-driven Drug Discovery And LicensingProprietary AI platforms that integrate large molecular and patient data can industrialize drug discovery and safety prediction, enabling scalable, higher‑margin licensing and royalty revenue through partnerships.
Biologics Manufacturing Commercial ValidationBiologics manufacturing platform's commercial validation via a licensing agreement supports the case for expanding contract and licensing revenues as additional partnerships are secured.
Cost Reduction And Capital EfficiencyManagement's transformation toward a leaner, capital-efficient operating model, including substantial headcount reductions and site consolidation, should lower operating costs and support improved cash generation.
Bears Say
Execution, Partner Dependence And Legal/regulatory RisksExecution risk is elevated due to reliance on partners, competitive pressures, regulatory hurdles, currency and macroeconomic headwinds, and potential intellectual property or legal disputes that could impair growth.
Near-term Restructuring Costs And Profitability PressureExtensive restructuring to simplify operations and transition to an asset‑light model requires sizeable upfront costs that will pressure near‑term profitability before cost savings are realized.
Weak Early-stage Demand And Moderating Partnership RevenueWeakness in early-stage discovery services, driven by constrained biotech funding and more disciplined pharma R&D, is reducing demand and moderating revenues as partner programs move into lower-investment phases.
Evotec AG News
EVO FAQ
What was Evotec AG’s price range in the past 12 months?
Evotec AG lowest stock price was $2.31 and its highest was $4.80 in the past 12 months.
What is Evotec AG’s market cap?
Evotec AG’s market cap is $1.11B.
When is Evotec AG’s upcoming earnings report date?
Evotec AG’s upcoming earnings report date is May 06, 2026 which is tomorrow.
How were Evotec AG’s earnings last quarter?
Evotec AG released its earnings results on Apr 08, 2026. The company reported $0.047 earnings per share for the quarter, beating the consensus estimate of -$0.144 by $0.191.
Is Evotec AG overvalued?
According to Wall Street analysts Evotec AG’s price is currently Undervalued.
Does Evotec AG pay dividends?
Evotec AG pays a Monthly dividend of $0.072 which represents an annual dividend yield of N/A. See more information on Evotec AG dividends here
What is Evotec AG’s EPS estimate?
Evotec AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Evotec AG have?
Evotec AG has 355,755,550 shares outstanding.
What happened to Evotec AG’s price movement after its last earnings report?
Evotec AG reported an EPS of $0.047 in its last earnings report, beating expectations of -$0.144. Following the earnings report the stock price went up 4.264%.
Which hedge fund is a major shareholder of Evotec AG?
Currently, no hedge funds are holding shares in EVO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Evotec AG Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.67 (43.15% Upside)
$4.67 (43.15% Upside)
Blogger Sentiment
Bullish
EVO Sentiment 100%
Sector Average 72%
Sector Average 72%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.10%
12-Months-Change
Fundamentals
Return on Equity
-12.28%
Trailing 12-Months
Asset Growth
1.04%
Trailing 12-Months
Company Description
Evotec AG
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
EVO Company Deck
EVO Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a cautiously optimistic outlook driven by a transformational pivot and strong momentum in the Just-Evotec Biologics segment: sizable one-time and structural revenue gains (Sandoz deal, grants, growing non-Sandoz revenues), meaningful cash and cost-savings progress, and improved group EBITDA. However, material weakness persists in the Discovery & Preclinical Development segment (revenue declines and negative segment EBITDA), one-off license timing effects and external headwinds (early-stage funding softness, DoW budget cuts, FX) create near-term pressure. Management has a defined Horizon plan to realize ~EUR 75m run-rate savings and midterm targets (>EUR 1bn revenue by 2030; 20% adjusted EBITDA by 2028), suggesting the company expects the positives and structural actions to outweigh current operational challenges over time.View all EVO earnings summariesEVO Stock 12 Month Forecast
Average Price Target
$4.67
▲(43.15% Upside)
Technical Analysis
Pacira Pharmaceuticals
―
Supernus Pharmaceuticals
―
ANI Pharmaceuticals
―
Amphastar Pharmaceuticals
―
Collegium Pharmaceutical
―
Ownership Overview
―
Insiders
<0.01% Mutual Funds
0.15% Other Institutional Investors
99.85% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---